- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| Di | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 | 160 | GlobeNewswire (Europe) | Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE... ► Artikel lesen | |
| Di | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 25.07. | Lyell Immunopharma announces up to $100 million equity private placement | 1 | Seeking Alpha | ||
| 25.07. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces up to $100 Million Equity Private Placement | 3 | GlobeNewswire (USA) | ||
| 18.07. | Lyell Immunopharma registers 625,000 shares for resale | 1 | Seeking Alpha | ||
| 26.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Lyell Immunopharma price target raised to $10 from $1 at H.C. Wainwright | 1 | Investing.com | ||
| 23.06. | Lyell Immunopharma, Inc: Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series | 3 | GlobeNewswire (USA) | ||
| 17.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma | 140 | GlobeNewswire (Europe) | LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with... ► Artikel lesen | |
| 10.06. | Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments | 4 | Seeking Alpha | ||
| 09.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments | 152 | GlobeNewswire (Europe) | Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary... ► Artikel lesen | |
| 21.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Lyell Immunopharma reports Q1 results | 2 | Seeking Alpha | ||
| 13.05. | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | 237 | GlobeNewswire (Europe) | Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,080 | -10,89 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| AMGEN | 247,45 | +0,08 % | Amgen-Aktie leicht im Minus (244,6719 €) | An der US-amerikanischen Börse liegt das Wertpapier von Amgen aktuell im Minus. Das Wertpapier kostete zuletzt 284,48 US-Dollar. Die Amgen-Aktie verzeichnet gegenwärtig einen Kursverlust von 0,09 Prozent.... ► Artikel lesen | |
| BIOGEN | 115,40 | -0,13 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome | - Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period -
- Dravet syndrome is a rare genetic disease characterized by... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split | PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its... ► Artikel lesen | |
| BIOXXMED | 0,450 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 10-Q, Quarterly Report | ||
| OCUGEN | 0,876 | -0,99 % | Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease | MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,880 | -6,88 % | EQS-DD: Bio-Gate AG: Thomas Konradt, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
12.08.2025 / 17:40... ► Artikel lesen | |
| EDITAS MEDICINE | 2,600 | -1,40 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,367 | -1,61 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,306 | +7,07 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders | - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart,... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,660 | -2,35 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,430 | 0,00 % | Cellectar Biosciences Q2 2025 Earnings Preview | ||
| GALAPAGOS NV | 27,600 | -0,22 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 10,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.